Single Agent Polysaccharopeptide Delays Metastases and Improves Survival in Naturally Occurring Hemangiosarcoma

Table 2

Baseline characteristics of 15 dogs diagnosed with splenic hemangiosarcoma randomized to one of three doses of I’m-Yunity.

	I'm-Yunity (polysaccharopeptide)
	25 mg/kg/day	50 mg/kg/day	100 mg/kg/day
	(𝑛=5)	(𝑛=5)	(𝑛=5)
Breed	1 mixed breed (20%)	2 mixed breed (40%)	2 mixed breed (40%)
	4 pure breed (80%)	3 pure breed (60%)	3 pure breed (60%)
Age (years)	9.0 ± 1.9	9.6 ± 2.7	8.6 ± 1.1
Weight (kg)	34.0 ± 7.0	28.2 ± 4.8	30.0 ± 12.8
Sex	1 female (20%)	2 female (40%)	1 female (20%)
	4 male (80%)	3 male (60%)	4 male (80%)
Metastatic disease present at enrollment	2 no (40%)	2 no (40%)	2 no (40%)
	3 yes (60%)	3 yes (60%)	3 yes (60%)
Time from diagnosis to study enrollment (days)	16 ± 9	23 ± 10	20 ± 8